GU Cancers 2022 | Clinical trials in adjuvant RCC
Hyung Kim, MD, Cedars-Sinai Medical Center, Los Angeles, CA, provides an overview of clinical trials in adjuvant renal cell carcinoma (RCC), highlighting the use of sunitinib and pembrolizumab for patients with high-risk RCC following nephrectomy as well as studies supporting their use, including KEYNOTE-564 (NCT03142334). This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.
Transcript (edited for clarity)
Tomorrow, I’ll be giving an update on the current status of adjuvant therapy for high-risk kidney cancer, following nephrectomy. There are two NCCN guideline recommended treatments. One drug is sunitinib and the other drug is pembrolizumab. I’ll discuss the clinical trials supporting the use of those drugs, the controversy surrounding their use as well. Right after my talk, there is a talk given by Tony Choueiri, where he is going to update us on a clinical trial called Keynote-564...
Tomorrow, I’ll be giving an update on the current status of adjuvant therapy for high-risk kidney cancer, following nephrectomy. There are two NCCN guideline recommended treatments. One drug is sunitinib and the other drug is pembrolizumab. I’ll discuss the clinical trials supporting the use of those drugs, the controversy surrounding their use as well. Right after my talk, there is a talk given by Tony Choueiri, where he is going to update us on a clinical trial called Keynote-564. That was a study comparing pembrolizumab to placebo in the adjuvant setting. So much of what I have to say may change based on what he presents as an update to the Keynote-564 trial.
Read more...
